Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
February 2026
in “
Mendeley Data
”
TLDR Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
The study investigates the relationship between androgenetic alopecia (AGA) and prostate cancer risk, focusing on the use of 5-alpha reductase inhibitors (5-ARIs). Utilizing data from the TriNetX network, the research analyzed a cohort of patients with AGA who were treated with 5-ARIs. The findings suggest that patients with AGA using 5-ARIs have a reduced risk of developing prostate cancer compared to those not using these inhibitors. This real-world evidence supports the potential protective effect of 5-ARIs against prostate cancer in patients with AGA. The study highlights the importance of considering 5-ARIs as a therapeutic option for reducing prostate cancer risk in this population.
